GlobeNewswire Inc | Feb 24, 2021 07:05AM EST

February 24, 2021

NESS ZIONA, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies(NASDAQ: SLGL), (Sol-Gel), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present an overview of the Company and provide a business update at the following virtual investor conferences.

Raymond James Institutional Investors Conference

Speakers: Dr. Alon Seri-Levy, Chief Executive Officer Date: 8:20 AM ET on March 1, 2021 Access: Available to conference participants.

H.C. Wainwright Global Life Sciences Conference

Speakers: Gilad Mamlok, Chief Financial Officer Date: March 9-10, 2021 Access: Available on demand to conference participants.

A webcast replay of the presentation at H.C. Wainwright Life Sciences Conference will be available in the Investors/Events and Presentations section of the Companys website atwww.sol-gel.com for 30 days.

AboutSol-Gel Technologies

Sol-Gelis a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.Sol-Gelleverages its proprietary microencapsulation technology platform for the development of Twyneo (benzoyl peroxide and tretinoin) cream, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of papulopustular rosacea. The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment ofpalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visitwww.sol-gel.com.

For further information, please contact:

Sol-Gel Contact:Gilad MamlokChief Financial Officer+972-8-9313433

Investor Contact:Michael LevitanSolebury Trout+1-646-378-2920mlevitan@soleburytrout.com

Source: Sol-Gel Technologies Ltd.